Evolution of the Average Target: Compass Therapeutics, Inc.

Evolution of the Target Price: Compass Therapeutics, Inc.

Changes in Analyst Recommendations: Compass Therapeutics, Inc.

4789daeb664.Soax2-W-k3KhGhqXjejPxVRFJRScefmlf2X4vkIP_3c.O8L6hLrh8hbNXUKgzN-biBgKQ02tQYPgLVWM_Rg_syEL8MbrqPqrC_dxXw~1932ecf29f9b5d7870658d4b5901ba45
24/09 Compass Therapeutics Shares Drop After Downgrade From Wedbush MT
23/09 Wedbush Downgrades Compass Therapeutics to Neutral From Outperform, Cuts Price Target to $1 From $5 MT
28/04 Raymond James Downgrades Compass Therapeutics to Market Perform From Outperform MT
28/04 Wedbush Lowers Compass Therapeutics Price Target to $5 From $8, Maintains Outperform Rating MT
05/01 William Blair Initiates Compass Therapeutics at Outperform MT
04/12 Canaccord Genuity Initiates Compass Therapeutics at Buy With $10 Price Target MT
04/12 Cantor Fitzgerald Initiates Compass Therapeutics at Overweight MT
02/04/25 Leerink Partners Upgrades Compass Therapeutics to Outperform From Market Perform, Adjusts PT to $6 From $4 MT
24/02/25 Guggenheim Initiates Compass Therapeutics at Buy With $12 Price Target MT
20/02/25 Piper Sandler Initiates Compass Therapeutics at Overweight MT
16/09/24 Ladenburg Thalmann Upgrades Compass Therapeutics to Buy From Neutral MT
31/01/23 Jefferies Starts Compass Therapeutics at Buy With $8 Price Target MT
28/01/23 Stifel Initiates Compass Therapeutics at Buy With $9 Price Target MT
17/12/22 EF Hutton Initiates Compass Therapeutics at Buy With $10.30 Price Target MT
11/11/22 Raymond James Adjusts Price Target on Compass Therapeutics to $8 From $5, Maintains Outperform Rating MT
04/11/22 HC Wainwright Adjusts Compass Therapeutics' Price Target to $10 From $12, Keeps Buy Rating MT
23/05/22 HC Wainwright Assumes Compass Therapeutics at Buy, Price Target Set at $12 MT
05/05/22 SVB Leerink Adjusts Compass Therapeutics' Price Target to $11 from $9, Keeps Outperform Rating MT
16/03/22 Ladenburg Thalmann Initiates Compass Therapeutics at Buy With $7 Price Target MT
20/01/22 B. Riley Starts Compass Therapeutics at Buy with $10 PT, Says Well-Positioned to Benefit from Potential Biotech Sector Turnaround MT
22/12/21 Raymond James Starts Compass Therapeutics at Outperform With $5 Price Target MT
21/12/21 SVB Leerink Starts Compass Therapeutics at Outperform With $12 Price Target MT
15/12/21 Wedbush Starts Compass Therapeutics at Outperform With $8 Price Target MT
20/11/21 Roth Capital Initiates Compass Therapeutics at Buy Rating With $15 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+386.73%
+15.19%
+22.02%
+9.85%
+68.92%
+18.94%
+7.76%
+20.98%
-7.69%
+32.69%
Average +57.54%
Weighted average by Cap. +21.24%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
1.130USD
Average target price
5.500USD
Spread / Average Target
+386.73%
High Price Target
12.00USD
Spread / Highest target
+961.95%
Low Price Target
1.000USD
Spread / Lowest Target
-11.50%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. CMPX Stock
  4. Consensus Compass Therapeutics, Inc.